Immuneering Corporation
IPOImmuneering | Deep Cyclic Inhibitors for MAPK-Driven Cancers
Public · Cambridge, United States · Founded 2008 · $25.0M raised
- Headquarters
- Cambridge, Massachusetts
- Employees
- 11–50
- Founded
- 2008
- Business Model
- B2B
- Website
- immuneering.com
- Total Funding
- $25.0M
- Last Round
- $25.0M Private EquityAug 2025
- Rounds
- 1
- Type
- Public
About
Clinical-stage oncology company developing Deep Cyclic Inhibitors — a new class of cancer therapies targeting MAPK-driven cancers.
Summary
Immuneering Corporation is a Biotech company based in Cambridge, United States, founded in 2008. It has raised $25.0M in total across 1 round, most recently a $25.0M Private Equity round in Aug 2025. Investors include Oppenheimer Holdings, SVB Leerink and Sanofi Ventures.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Sep 2025
Sign up to see all 2 rounds
Private Equity through IPO — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/immuneering-corporation"><img src="https://indexed.vc/api/badge/company/immuneering-corporation" alt="Immuneering Corporation on Indexed.vc" width="260" height="76" /></a>